IQVIA Holdings Inc. (NYSE:IQV) is among the 10 Best Consensus Buy-Rated Stocks to Invest in. Morgan Stanley lowered its price target on IQVIA Holdings Inc. (NYSE:IQV) to $240 from $265 but maintained an Overweight rating after the company’s quarterly results on February 11, 2026.

On February 10, 2026, IQVIA Holdings Inc. (NYSE:IQV) and the Duke Clinical Research Institute announced a collaboration to advance clinical research in obesity and related cardiometabolic trials. The partnership aims to set a new standard for collaboration between life science service companies and academic research organizations, focusing on accelerating clinical trial planning and delivery.

IQVIA reported fourth-quarter revenue of $4.36 billion on February 5, 2026, exceeding the $4.08 billion consensus estimate. CEO Ari Bousbib noted strong performance across all segments in 2025, with double-digit revenue and EPS growth, and the strongest quarter in R&DS net bookings. Expanded go-to-market efforts and AI-related investments supported topline growth in commercial and clinical businesses, positioning the company for 2026.

Read more at Yahoo Finance: Morgan Stanley Lowers its Price Target on IQVIA Holdings Inc. (IQV) to $240 but Maintains an Overweight Rating